Side-by-side comparison of AI visibility scores, market position, and capabilities
Rare disease drug discovery using patient-derived organoids and robotics to screen therapeutics matching real genetic mutations; YC and NSF backed with Stanford-validated pediatric heart disease breakthrough.
Rosebud Biosciences is a San Carlos-based drug discovery company that accelerates therapeutic development for rare diseases by screening drug candidates against patient-derived organoids — miniature 3D organ models grown from patients' own cells with matching genetic mutations — using robotic automation and machine learning to identify compounds that correct disease phenotypes at a scale impossible with traditional cell line testing. Founded in 2020 and backed by Y Combinator, NSF, and other investors with $440,000 in revenue, Rosebud has achieved Stanford-validated research breakthroughs published in prestigious scientific journals, including discovering a novel drug target for pediatric heart disease.
$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.